Andrew M. Chanen

Rationale and first results of developing at-risk (prodromal) criteria for bipolar disorder.

M. Berk, J. Klosterkötter, A. Bechdolf, 2012, Current pharmaceutical design.

ENACT: a protocol for a randomised placebo-controlled trial investigating the efficacy and mechanisms of action of adjunctive N-acetylcysteine for first-episode psychosis

M. Berk, P. McGorry, K. Allott, 2019, Trials.

Youth Depression Alleviation‐Augmentation with an anti‐inflammatory agent (YoDA‐A): protocol and rationale for a placebo‐controlled randomized trial of rosuvastatin and aspirin

A. Mackinnon, M. Berk, C. Davey, 2018, Early intervention in psychiatry.

Differences between first episode schizophrenia and schizoaffective disorder

A. Mackinnon, M. Lambert, D. Schöttle, 2013, Schizophrenia Research.

Depressive symptoms in first episode schizophrenia spectrum disorder

A. Mackinnon, M. Berk, M. Lambert, 2012, Schizophrenia Research.

Transdiagnostic risk identification: A validation study of the Clinical High At Risk Mental State (CHARMS) criteria

H. Yuen, J. Hartmann, P. Amminger, 2024, Psychiatry Research.

Mood and Anxiety Disorders in Women: Borderline personality disorder: Sex differences

Andrew M. Chanen, 2006 .

The Lancet Psychiatry Commission on youth mental health.

L. Valmaggia, M. Alvarez-Jimenez, P. Gonsalves, 2024, The lancet. Psychiatry.